EMBECTA CORPORATION
Embecta Corp (EMBC) is a healthcare company with a market capitalisation of about $836.3m that specialises in devices and consumables used in diabetes care. Investors should know it operates in a steady, necessity-driven market where product reliability, regulatory approvals and reimbursement matter. Growth may come from product innovation, expanding geographic reach and rising prevalence of diabetes, but margins and volume can be influenced by competition, pricing pressure and supply-chain costs. As a mid‑cap company, Embecta can offer upside if execution and adoption go well, yet it may also be more volatile than larger peers. Key considerations include product pipeline, manufacturing scale, regulatory pathway, and cash flow stability. This summary is educational and not personal financial advice: values can rise or fall and past performance is no guarantee of future returns. Investors should research company reports, check recent financials, and consider their own risk tolerance or consult a regulated adviser before acting.
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding EMBECTA's stock with a target price of $16.67, indicating moderate expectations.
Financial Health
Embecta Corp is performing well with strong revenue and cash flow, indicating good financial stability.
Dividend
Embecta Corp's dividend yield of 5.88% is appealing for investors seeking dividend income. If you invested $1000 you would be paid $58.80 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring EMBC
At-Home Treatment Revolution | FDA Approval Impact
The FDA's approval of an injectable, at-home version of Eisai and Biogen's Alzheimer's drug signals a major shift in chronic disease management. This creates an investment opportunity in companies that develop advanced drug delivery systems and support at-home patient care.
Published: September 1, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Diabetes device focus
The company operates in a steady, necessity-driven market where innovation and product reliability can support growth, though competitive pressure may affect returns.
Global market opportunity
Rising prevalence of diabetes worldwide can expand addressable markets, but regulatory and reimbursement differences across regions add complexity and risk.
Execution matters most
Manufacturing scale, regulatory milestones and supply‑chain resilience drive outcomes; investors should weigh these operational factors alongside financial metrics.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.